Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

41. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis

Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review (...) and meta-analysis Huang B, Huang Y, Li Y, Yao H, Jing X, Huang H, Li J CRD summary This review found that the use of proton-pump inhibitors with clopidogrel, for patients with coronary artery disease, was associated with increased risks of major adverse cardiac events and acute coronary syndrome. In general, the review was well conducted and the authors' conclusions are likely to be reliable. Authors' objectives To assess whether proton-pump inhibitors with clopidogrel increased the risks of major

DARE.2013

42. Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study

Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study 23277305 2013 02 12 2013 04 10 2014 11 20 1524-4539 127 6 2013 Feb 12 Circulation Circulation Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. 673-80 10.1161/CIRCULATIONAHA.112.124248 We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent (...) ) occurrences of any of the primary outcome events (e.g., cardiovascular death, myocardial infarction, and stroke) as well as on other ischemic events, such as urgent revascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thrombotic events. In the PLATelet inhibition and patient Outcomes (PLATO) study, 18 624 patients presenting with acute coronary syndromes randomly received ticagrelor (n=9333) or clopidogrel (n=9291). Cox proportional hazard models were used to calculate

EvidenceUpdates2013

43. The antiplatelet effects of ticlopidine and clopidogrel.

The antiplatelet effects of ticlopidine and clopidogrel. The antiplatelet effects of ticlo... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1998 ) Volume: 129 , Issue: 5 , Pages: 394-405 PubMed: Available from or Find this paper at: Abstract Ticlopidine and clopidogrel achieve antiplatelet effects by inhibiting the binding of adenosine 5'-disphosphate to its platelet receptor (...) , and diabetic retinopathy. Clopidogrel was recently approved by the U.S. Food and Drug Administration for the reduction of ischemic events in patients with recent myocardial infarction, stroke, or peripheral arterial disease (incidence, 5.32% per year compared with 5.83% per year for aspirin; P = 0.043) with no added risk for neutropenia. The combination of clopidogrel and aspirin, as well as the utility of clopidogrel in other patient populations and in stenting, requires further study. Ticlopidine

Annals of Internal Medicine2013

44. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Aspirin to prevent cardiovascular... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2009 ) Volume: 150 , Issue: 6 , Pages: 379-386 PubMed: Available from or Find this paper at: Abstract BACKGROUND: The optimal aspirin dose for the prevention of cardiovascular events (...) remains controversial. OBJECTIVE: To assess the incidence of and risk factors for adverse clinical outcomes by investigator-determined aspirin dose in a primary prevention trial. DESIGN: Post hoc observational analyses of data from a double-blind, placebo-controlled, randomized trial. SETTING: Outpatient. PATIENTS: 15 595 patients with cardiovascular disease or multiple risk factors. INTERVENTION: Clopidogrel, 75 mg/d, or placebo, with aspirin, 75 to 162 mg/d, as selected by the investigators

Annals of Internal Medicine2013

45. Annals of Internal Medicine Article Aspirin to Prevent Cardiovascular Disease : The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding

Annals of Internal Medicine Article Aspirin to Prevent Cardiovascular Disease : The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding Annals of Internal Medicine Artic... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2009 ) Volume: 150 , Issue: 1539-3704 (Electronic) LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't RN - 0 (Platelet Aggregation (...) Inhibitors) RN - 50-78-2 (Aspirin) RN - 55142-85-3 (Ticlopidine) RN - 90055-48-4 (clopidogrel) SB - AIM SB - IM , Pages: 379-386 Find this paper at: Abstract Background: The optimal aspirin dose for the prevention of cardiovascular events remains controversial. Objective: To assess the incidence of and risk factors for adverse clinical outcomes by investigator-determined aspirin dose in a primary prevention trial. Design: Post hoc observational analyses of data from a double-blind, placebo-controlled

Annals of Internal Medicine2013

46. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable

Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of clopidogrel plus aspirin, compared with aspirin alone, for the prevention of stroke in patients with uncomplicated atrial fibrillation. The authors concluded

NHS Economic Evaluation Database.2013

47. Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin

Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Article Text Aetiology Cohort study Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Ron Waksman 1

Evidence-Based Medicine (Requires free registration)2013

48. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome ? a systematic review

Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome ? a systematic review Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome – a systematic review Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome – a systematic review Jaspers Focks J, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW CRD summary This review concluded (...) that the evidence for the clinical consequences of clopidogrel given with proton-pump inhibitors was controversial. Prospective clinical studies did not support any adverse effects. These conclusions reflect the evidence and seem reliable; the limitations of the evidence should be borne in mind. Authors' objectives To evaluate the impact of clopidogrel plus proton-pump inhibitors on platelet function and cardiovascular outcomes for patients with acute coronary syndrome or stents for stable coronary disease

DARE.2013

49. Clopidogrel: risk of acquired haemophilia

Clopidogrel: risk of acquired haemophilia Clopidogrel: risk of acquired haemophilia Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Clopidogrel: risk of acquired haemophilia From: Published: 9 December 2013 Therapeutic area: Reports of acquired haemophilia have been received in association with clopidogrel. Article date: December 2013 Clopidogrel is a thienopyridine, inhibiting platelet activation and aggregation. It is indicated for prevention (...) authorisation) holder in association with clopidogrel, four of which were published case reports. This number of reports should be considered in the context of the very high use of clopidogrel (more than 153 million patients worldwide). The case reports described patients aged between 65 years and 81 years, with no previous history of abnormal haemostasis. In six cases, it was reported that symptoms of acquired haemophilia resolved after stopping clopidogrel and corrective treatment (including steroids

MHRA Drug Safety Update2013

50. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.

Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. 23953385 2013 08 19 2013 08 30 2016 06 27 1474-547X 382 9892 2013 Aug 17 Lancet (London, England) Lancet Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY (...) ACS trial. 605-13 10.1016/S0140-6736(13)61451-8 S0140-6736(13)61451-8 Treatment with prasugrel and aspirin improves outcomes compared with clopidogrel and aspirin for patients with acute coronary syndrome who have had angiography and percutaneous coronary intervention; however, no clear benefit has been shown for patients managed first with drugs only. We assessed outcomes from the TRILOGY ACS trial based on whether or not patients had coronary angiography before treatment was chosen. TRILOGY ACS

Lancet2013

52. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. 23415013 2013 04 01 2013 04 08 2015 06 16 1474-547X 381 9872 2013 Mar 30 Lancet (London, England) Lancet Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. 1107-15 10.1016/S0140 (...) -6736(12)62177-1 S0140-6736(12)62177-1 If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, antiplatelet therapy with aspirin and clopidogrel is indicated, but such triple therapy increases the risk of serious bleeding. We investigated the safety and efficacy of clopidogrel alone compared with clopidogrel plus aspirin. We did an open-label, multicentre, randomised, controlled trial in 15 centres in Belgium and the Netherlands. From November, 2008

Lancet2013

53. Clopidogrel in infants with systemic-to-pulmonary-artery shunts.

Clopidogrel in infants with systemic-to-pulmonary-artery shunts. 23782178 2013 06 20 2013 06 28 2013 11 21 1533-4406 368 25 2013 Jun 20 The New England journal of medicine N. Engl. J. Med. Clopidogrel in infants with systemic-to-pulmonary-artery shunts. 2377-84 10.1056/NEJMoa1114588 Infants with cyanotic congenital heart disease palliated with placement of a systemic-to-pulmonary-artery shunt are at risk for shunt thrombosis and death. We investigated whether the addition of clopidogrel (...) to conventional therapy reduces mortality from any cause and morbidity related to the shunt. In a multicenter, double-blind, event-driven trial, we randomly assigned infants 92 days of age or younger with cyanotic congenital heart disease and a systemic-to-pulmonary-artery shunt to receive clopidogrel at a dose of 0.2 mg per kilogram of body weight per day (467 infants) or placebo (439 infants), in addition to conventional therapy (including aspirin in 87.9% of infants). The primary efficacy end point

NEJM2013

54. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. 23803136 2013 07 04 2013 07 12 2015 07 31 1533-4406 369 1 2013 Jul 04 The New England journal of medicine N. Engl. J. Med. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. 11-9 10.1056/NEJMoa1215340 Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection (...) against subsequent stroke than aspirin alone. In a randomized, double-blind, placebo-controlled trial conducted at 114 centers in China, we randomly assigned 5170 patients within 24 hours after the onset of minor ischemic stroke or high-risk TIA to combination therapy with clopidogrel and aspirin (clopidogrel at an initial dose of 300 mg, followed by 75 mg per day for 90 days, plus aspirin at a dose of 75 mg per day for the first 21 days) or to placebo plus aspirin (75 mg per day for 90 days). All

NEJM2013

56. Adding clopidogrel to aspirin did not reduce recurrent stroke and increased bleeding in lacunar stroke.

Adding clopidogrel to aspirin did not reduce recurrent stroke and increased bleeding in lacunar stroke. ACP Journal Club. Adding clopidogrel to aspirin did not reduce recurrent stroke and increased bleeding in lacunar stroke. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My (...) Bibliography Citation manager Format Create File 1 selected item: 23247951 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Dec 18;157(12):JC6-2. doi: 10.7326/0003-4819-157-12-201212180-02002. ACP Journal Club. Adding clopidogrel to aspirin did not reduce recurrent stroke and increased bleeding in lacunar stroke. 1 , . 1 University

Annals of Internal Medicine2012

57. Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies

Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies Biancari F (...) , Airaksinen KE, Lip GY CRD summary The authors concluded that, contrary to analyses of randomised controlled trial data, observational studies showed that clopidogrel before coronary artery bypass grafting increased the risks of death after surgery, reoperation for bleeding, blood loss and needing a blood transfusion. The limitations of the evidence available, and the differences between studies, make the reliability of the authors' conclusions unclear. Authors' objectives To assess the impact

DARE.2012

58. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion after off-pump procedures) randomised study

Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion after off-pump procedures) randomised study 22942294 2012 11 15 2013 01 15 2016 11 25 1468-201X 98 23 2012 Dec Heart (British Cardiac Society) Heart Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary (...) arteRY bypaSS occlusion After off-pump procedures) randomised study. 1710-5 10.1136/heartjnl-2012-302449 To determine the individual variability in the response to aspirin and/or clopidogrel and its impact on graft patency after off-pump coronary artery bypass grafting. A single-centre prospective randomised controlled study designed according to the Consolidated Standards of Reporting Trials statement. Randomisation was obtained by a computer-generated algorithm. University medical school in Italy. 300 patients who

EvidenceUpdates2012

59. Outcomes of patients receiving clopidogrel prior to cardiac surgery

Outcomes of patients receiving clopidogrel prior to cardiac surgery Outcomes of patients receiving clopidogrel prior to cardiac surgery Outcomes of patients receiving clopidogrel prior to cardiac surgery Vorobcsuk A, Aradi D, Farkasfalvi K, Horvath IG, Komocsi A CRD summary This review found that concomitant treatment of clopidogrel prior to surgery in patients who underwent cardiac surgery was associated with higher mortality and significantly increased risk of bleeding-related complications (...) . Uncertainty about the completeness of the search and flaws in the presentation of the results mean that the results and conclusions should be interpreted with some caution. Authors' objectives To assess the effect of treatment with clopidogrel on clinical outcomes in patients having cardiac surgery. Searching PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from January 2001 to May 2010. Search terms were reported. There were no language restrictions. Reference lists

DARE.2012

60. Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis

Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis Zhou YH, Wei X, Lu J, Ye XF, Wu MJ, Xu JF, Qin YY, He J CRD summary The addition of aspirin to clopidogrel resulted in small relative reductions (...) in major cardiovascular events, myocardial infarction and stroke, but it resulted in a relative increase in major bleeding events. The authors' conclusion reflects the evidence presented and seems reliable. Authors' objectives To evaluate the benefits and harms of combined aspirin and clopidogrel therapy on major cardiovascular outcomes. Searching PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched until March, 2011; search terms were reported. To locate

DARE.2012